Ketamine for major depression: New tool, new questions
Ketamine was once used mainly as an anesthetic on battlefields and in operating rooms. Now this medication is gaining ground as a promising treatment for some cases of major depression, which is the leading cause of disability worldwide. In the US, recent estimates show 16 million adults had an episode of major depression in the course of a year. Suicide rates rose substantially between 1999 and 2016, increasing by more than 30% in 25 states. Because of its rapid action, ketamine could have a role to play in helping to prevent suicide. Why is ketamine exciting for treating depression? If a person responds to ketamine, it can rapidly reduce suicidality (life-threatening thoughts and acts) and relieve other serious symptoms of depression. Ketamine also can be effective for treating depression combined with anxiety. Other treatments for suicidal thoughts and depression often take weeks or even months to take effect, and some people need to try several medications or approaches to gain relief. This is true for talk therapies, antidepressant medicines, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT), which is currently the most effective treatment for major depression that fails to respond to other therapies. Are there different types of ketamine? Two main types of ketamine are used to treat major depression that hasn’t responded to two or more medications (treatment-resistant depression). Racemic ketamine, which is most often given as an infusi...
CONCLUSIONS: It appears that cycling has a positive effect on walking speed, walking ability and balance. Functional electrical stimulation combined with cycling has positive effects on balance beyond cycling alone. PMID: 31227660 [PubMed - in process]
CONCLUSIONS: No significant association was obtained between the four-factor structures of depression in MADRS and serotonin transporter and receptor SNPs in a study with a small sample size. This study evaluates whether depression symptom-clusters have distinct genotypic determinants and necessitates more comprehensive studies for unravelling the genetic determinants of depression. PMID: 31228794 [PubMed - as supplied by publisher]
Anyone have any advice for treating hiccups during endoscopy (assume patient is adequately sedated with propofol). It happens infrequently and typically resolves within a few minutes- but very annoying when it occurs during a critical part of a case!
Not even sure why I'm writing this as there's nothing I could "do", but you know what they say about talking out your problems. I'm having extreme anxiety and sadness about my upcoming move for residency. Not nightmares, but I've been having bad dreams about the move all week. I'm a Southern California native. Went to a southern california UC for undergrad and went to that same UC for medical school. Had the great fortune of commuting from home for all 8 years. I'm moving out of state this... Advice needed (Anxiety and Sadness about moving)
Conclusion In patients with advanced non-squamous NSCLC, the feasible dose of apatinib given with standard-dose pemetrexed and carboplatin was 500 mg/day schedule 2/1. The schedule was generally well tolerated and demonstrated promising clinical benefit in NSCLC.
Conclusion GX showed promising efficacy in patients with SRCC. GX could be considered as a treatment option for patients with SRCC and should be confirmed in larger clinical trials.
Authors: Long JD PMID: 31225773 [PubMed - as supplied by publisher]
In this study, we will use a mixed methods multi-center study design. In phase one, we will investigate the mental health literacy of PHC practitioners to identify areas in need of development. Based on the needs identified, we will develop and test a mobile health application to screen for common youth mental health problems in phase two. In phase three, we will implement and evaluate a tiered education and training program in the use of the m-health application. In the final phase, we will evaluate the acceptability and feasibility of the m-health application in PHC centres across South Africa and Zambia. Evidence sugges...